Precipio Inc. (PRPO)
NASDAQ: PRPOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRPO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $31.11M
- Forward P/E
- 44.49
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 17.30 – 33.63
- Day range
- 17.30 – 19.11
- Volume / Avg
- 35.65K / 79.50K
- Beta
- —
- Shares outstanding
- 1.79M
52-week range
PRPO stock today
On Nov 20, PRPO ended the session at $17.35, shedding $1.14 (6.17%), versus the S&P 500's 3.70% decline. Trading was light, with 35.65K shares changing hands, about 45% of the average daily volume. Shares are 48.4% below their 52-week high of $33.63, set on May 6, 2026 and 0.3% above the 52-week low of $17.30, near the bottom of the past year's range.
PRPO is down 24.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.2%. Precipio has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Precipio
Company profilePrecipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. Ilan Danieli
- Headquarters
- New Haven, CT
- Employees
- 61
- Website
- precipiodx.com
Financial highlights
Full financialsIn fiscal 2025, Precipio generated $24.0 million in revenue, up 29.8% from fiscal 2024, its 8th consecutive year of revenue growth. Precipio reported a net loss of $363,000, compared with a loss of $4.3 million a year earlier. Gross margin was 44.5% (up from 40.8%) and operating margin -5.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $24.05M | $18.53M | $15.20M | $9.41M | $8.85M |
| Growth | +29.77% | +21.95% | +61.46% | +6.36% | +45.26% |
| Net income | $-363.00K | $-4.29M | $-5.85M | $-12.18M | $-8.52M |
| EPS (diluted) | $-0.23 | $-2.93 | $-4.51 | $-10.73 | $-0.40 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.05 vs —
PRPO news
All PRPO newsPrecipio peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EYPTEyePoint Inc. | 0.2342 | -11.36% | $26.65M | vs PRPO |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs PRPO |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs PRPO |
| CIRCCircle8 Group Inc. | 0.1361 | -12.25% | $15.99M | vs PRPO |
| BNGOBionano Genomics Inc. | 0.8222 | -7.11% | $11.50M | vs PRPO |
| ASTCAstrotech Corporation (DE) | 3.50 | -0.85% | $7.45M | vs PRPO |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs PRPO |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs PRPO |
Indexes, lists and sector
Precipio stock FAQ
What is Precipio's stock price today?
PRPO last traded at $17.35 as of Nov 20, 4:00 PM EST, down 6.17% on the day. Prices are delayed at least 15 minutes.
Does Precipio pay a dividend?
No. Precipio does not currently pay a regular cash dividend.
Who is Precipio's CEO?
Mr. Ilan Danieli is the chief executive officer of Precipio Inc., which has about 61 employees.
Has PRPO ever split its stock?
Yes. The most recent PRPO stock split was a 1-for-20 split on Sep 22, 2023, one of 2 splits on record.
What is the PRPO 52-week high?
The 52-week high for PRPO is $33.63 and the 52-week low is $17.30. The stock is currently 48.4% below its high.